Scarica l'app Stockscreener
17.85
2.06%
0.36
Pre-mercato:
17.95
0.10
+0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Precedente Chiudi:
$17.49
Aprire:
$17.53
Volume 24 ore:
1.30M
Relative Volume:
0.89
Capitalizzazione di mercato:
$2.07B
Reddito:
$674.41M
Utile/perdita netta:
$-173.05M
Rapporto P/E:
-11.63
EPS:
-1.5343
Flusso di cassa netto:
$-48.07M
1 W Prestazione:
+7.21%
1M Prestazione:
+1.54%
6M Prestazione:
+44.77%
1 anno Prestazione:
+2.41%
Intervallo 1D:
$17.36
$18.00
Intervallo di 1 settimana:
$16.41
$18.35
Portata 52W:
$9.82
$18.92
Novocure Ltd Stock (NVCR) Company Profile
Nome
Novocure Ltd
Settore
Industria
Telefono
44 (0)15 3475 6700
Indirizzo
NO. 4 THE FORUM, ST. HELIER
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
17.85 | 2.04B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-12-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Iniziato | SVB Securities | Outperform |
| 2023-07-31 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2023-05-16 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Reiterato | H.C. Wainwright | Buy |
| 2022-11-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Downgrade | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-08 | Iniziato | Loop Capital | Buy |
| 2022-02-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2022-01-03 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-14 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-01-25 | Reiterato | Piper Sandler | Overweight |
| 2020-09-23 | Iniziato | Northland Capital | Outperform |
| 2020-09-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Downgrade | Truist | Buy → Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Perform |
| 2020-05-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Aggiornamento | SunTrust | Hold → Buy |
| 2019-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2018-11-02 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Iniziato | Evercore ISI | Outperform |
| 2018-04-18 | Reiterato | Mizuho | Buy |
| 2018-02-23 | Reiterato | Mizuho | Buy |
| 2017-05-24 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Reiterato | Wedbush | Outperform |
| 2016-01-19 | Iniziato | Barclays | Underweight |
| 2015-12-02 | Iniziato | Deutsche Bank | Hold |
Mostra tutto
Novocure Ltd Borsa (NVCR) Ultime notizie
NovoCure Ltd stock (JE00B6T5S470): Focus on Tumor Treating Fields technology as investors weigh rece - AD HOC NEWS
Frank Leonard’s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR) - Yahoo Finance
Have Insiders Sold NovoCure Shares Recently? - simplywall.st
NovoCure Limited Adopts Amended and Restated 2024 Omnibus Incentive Plan and Reports 2026 Annual Meeting Results - Minichart
Novocure Insider Sold Shares Worth $614,635, According to a Recent SEC Filing - marketscreener.com
NovoCure Limited Elects Frank Leonard as Director, Effective June 3, 2026 - marketscreener.com
NovoCure (NASDAQ: NVCR) investors OK directors and tight 2024 incentive plan vote - Stock Titan
NovoCure (NVCR) CEO sells 34,273 shares in tax-related transaction - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and options in new equity awards - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and options in 2026 award - Stock Titan
NovoCure (NVCR) director receives new share and stock option awards - Stock Titan
NovoCure (NVCR) grants RSUs and stock options to director Scannell - Stock Titan
NovoCure (NASDAQ: NVCR) director granted RSUs and 16,999 stock options - Stock Titan
[Form 4] NovoCure Ltd Insider Trading Activity - Stock Titan
NovoCure (NASDAQ: NVCR) awards director new RSUs and stock options - Stock Titan
NovoCure (NASDAQ: NVCR) grants RSUs and stock options to director Vernon W. Anthony - Stock Titan
NovoCure Ltd stock (JE00B6T5S470): shares jump after double-digit move puts focus on valuation - AD HOC NEWS
Is It Too Late to Buy NovoCure Ltd (NVCR) After 11.4% Rally? GF Value Says Undervalued - GuruFocus
[144] NovoCure Ltd SEC Filing - Stock Titan
Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday - The Motley Fool
NVCR Technical Analysis & Stock Price Forecast - Intellectia AI
Tax-driven NovoCure (NASDAQ: NVCR) director share sale after RSU vesting - Stock Titan
NovoCure (NVCR) director executes 2,945-share sell-to-cover for RSU tax - Stock Titan
NovoCure (NVCR) director sells 2,945 shares to cover RSU tax withholding - Stock Titan
NovoCure (NVCR) director sells 2,945 shares in tax-related trade - Stock Titan
NovoCure (NVCR) director sells 2,945 shares to cover RSU tax - Stock Titan
NovoCure (NVCR) director Hung disposes shares in mandated tax-related sale - Stock Titan
A Look At NovoCure (NVCR) Valuation As Shares Show Mixed Recent Performance - simplywall.st
NovoCure Ltd stock (JE00B6T5S470): Nasdaq-listed cancer therapy group in focus after recent volatili - AD HOC NEWS
Piper Sandler Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $27 - Moomoo
NovoCure Stock Still Up Ahead of Cancer Trial Data - Bez Kabli
NovoCure Ltd stock (JE00B6T5S470): Q1 2026 growth meets one?time hit - AD HOC NEWS
NVCR Technical Analysis | Trend, Signals & Chart Patterns | NOVOCURE LTD (NASDAQ:NVCR) - ChartMill
NovoCure Earnings Call Highlights Growth, One-Time Hit - TipRanks
NovoCure LimitedOrdinary Shares (NQ: NVCR - FinancialContent
NovoCure Ltd stock (JE00B6T5S470): mixed Q4 2025 results and new Oppenheimer upgrade draw investor f - AD HOC NEWS
NovoCure (NVCR) Is Up 9.7% After Raising 2026 Revenue Outlook And Posting Stronger Q1 Sales - Sahm
NovoCure Ltd stock (JE00B6T5S470): Up 40% YTD on oncology innovation - AD HOC NEWS
A Look At NovoCure (NVCR) Valuation After Raised 2026 Revenue Guidance And Q1 Beat - simplywall.st
Soleus discloses 10.49M-share stake in NovoCure (NASDAQ: NVCR) - Stock Titan
Oncology Company Given Neutral Rating as Q1/26 Beat Sets Up Catalyst - Streetwise Reports
NovoCure Ltd (MEX:NVCRN) Stock Price & 30 Year Financial Data - GuruFocus
NovoCure Ltd (MEX:NVCRN) DCF Valuation - GuruFocus
NovoCure Ltd (MEX:NVCRN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
NovoCure Ltd (MEX:NVCRN) Stock Earnings Transcripts - GuruFocus
Oncology Co. Tests Advanced Cancer Treatments, Reports Q1 2026 Financial Results - Streetwise Reports
MSN Money - MSN
Why NovoCure (NVCR) Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher - Sahm
3 Overlooked Stocks Set to Soar in 2026 - Yahoo Finance
International Markets and NovoCure (NVCR): A Deep Dive for Investors - Yahoo Finance
Wells Fargo Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $17 - Moomoo
Novocure Ltd Azioni (NVCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):